hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06264830 id: 202307103DIPC briefTitle: 3D Visualization System in Highly Myopic Cataract Operation acronym: 3D-HiMCO overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12 date: 2024-12 date: 2024-02-20 date: 2024-04-16 name: National Taiwan University Hospital class: OTHER name: Alcon Research briefSummary: This study aims to investigate the impact of depth of field differences between the use of the 3D imaging system (NGENUITY® 3D Visualization System, Alcon, TX, USA) and conventional optical microscope in cataract surgery for highly myopic patients on intraoperative parameters and outcomes. conditions: Cataract conditions: High Myopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Alcon-NGENUITY®(NG)-system name: Standard cataract operation measure: Number of times of Microscopic focus adjustment, measured by counting from the video recordings measure: Total moving distance in millimeter of microscope-lens-system relative to suspension arm, measured by ruler set on microscope measure: Distance of subjective focus change in millimeter between corneal surface and surface of posterior capsule, measured by ruler set on microscope measure: Total operation time measure: Cumulative dissipated energy (CDE) of phacoemulsification, that is automatically measured and demonstrated on the screen of phacoemulsification machine (Centurion) measure: Number of Participants with intraoperative complication measure: Best-corrected visual acuity of the operated eye of Participants at each postoperative follow-up within 3 month, measured with Snellen chart under standard condition (6 meters in distance and standard illumination of environment) measure: Number of Participants with post-operative complication measure: Intraocular pressure of the operated eye of participants at each postoperative follow-up within 3 month, measured with pneumatic tonometer sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology, National Taiwan University Hospital city: Taipei zip: 100 country: Taiwan name: Tzyy-Chang Ho, MD role: CONTACT phone: 886-2-23123456 phoneExt: 62579 email: hotc@ntuh.gov.tw name: Cheng-Yung Lee, MD role: CONTACT phone: 886-2-23123456 phoneExt: 65190 email: G05875@hch.gov.tw lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06264817 id: EC 48 LyberT briefTitle: Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. acronym: LyberT overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2025-04-15 date: 2024-02-20 date: 2024-02-20 name: Thuasne class: INDUSTRY briefSummary: This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess compared to the compression bandages to manage the volume of upper limb lymphedema in patients with breast cancer related lymphedema conditions: Lymphedema of Upper Limb studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, multi-center, interventional, controlled-randomized, single blinded study primaryPurpose: TREATMENT masking: SINGLE maskingDescription: For the same patient, all measurements will be performed as far as possible by the same health professional who doesn't have the knowledge of patient's group. whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: MOBIDERM Autofit Armsleeve name: Compressive bandaging measure: Volume excess variation measure: Resource consumption measure: Resource consumption measure: Resource consumption measure: Lymphedema related Quality of life (QoL) measure: Doctors' opinion on improving the patient's health condition measure: Patient's opinion on Global Impression of Change measure: Satisfaction about the device measure: The safety measure: Compliance to treatment measure: General quality of life (QoL) measure: Skin elasticity measure: Ttissue induration sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pinar BORMAN city: Ankara country: Turkey name: Pinar BORMAN role: CONTACT lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06264804 id: [2023] No. 86 briefTitle: Risk Factors for Progressive Suction Loss in Corneal Refractive Surgery overallStatus: RECRUITING date: 2024-02-16 date: 2024-07-01 date: 2024-12-01 date: 2024-02-20 date: 2024-04-02 name: Yifeng Yu class: OTHER briefSummary: The goal of this Prospective observational studiesis to Characteristics of progressive suction loss. conditions: Refractive Surgery studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 800 type: ESTIMATED measure: Identify risk factors for progressive suction loss sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Yuyifeng status: RECRUITING city: Nanchang state: Jiangxi zip: 330008 country: China name: yifeng Yu, Doctorate role: CONTACT phone: +8613979180258 email: 171018170@qq.com lat: 28.68396 lon: 115.85306 hasResults: False
nctId: NCT06264791 id: STUDY00018516 id: K99AA030591 type: NIH link: https://reporter.nih.gov/quickSearch/K99AA030591 briefTitle: Stress-motivated Alcohol Use as a Value-based Decision-making Process overallStatus: RECRUITING date: 2024-02-01 date: 2024-10-01 date: 2024-10-01 date: 2024-02-20 date: 2024-02-20 name: University of Washington class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: The goal of this experimental study is to improve our understanding of the effects of stress on the decision to consume (more) alcohol in regular drinkers. The main question\[s\] it aims to answer are:
* How does psychological stress affect the decision to consume (more) alcohol? Participants will be randomly assigned to one of four conditions (stress alcohol, stress no alcohol, no stress alcohol, no stress no alcohol) and complete a value-based decision-making task twice (once before and once after the manipulations). conditions: Psychological Stress conditions: Alcohol Intoxication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 160 type: ESTIMATED name: Stress name: Alcohol measure: Proportion of choices for alcoholic over non-alcoholic drinks. sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Washington status: RECRUITING city: Seattle state: Washington zip: 98105 country: United States name: Jonas Dora, PhD role: CONTACT phone: 206-741-6330 email: jdora@uw.edu lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06264778 id: 2023013 briefTitle: Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-11-01 date: 2025-12-31 date: 2024-02-20 date: 2024-02-20 name: Shandong University class: OTHER briefSummary: This pilot clinical trial plans to carry out dabrafenib adjuvant therapy combined with lesion curettage after fenestrated decompressive surgery for BRAF mutation-positive multicystic ameloblastoma to explore the effectiveness of this therapy in preventing tumor recurrence, reducing or even avoiding postoperative deformity and dysfunction. effect. Based on this, we plan to launch a prospective clinical study of dabrafenib in the treatment of BRAF V600E ameloblastoma, verify the feasibility of drug treatment or drug-assisted treatment of ameloblastoma, and provide patients with a safer Effective new treatment options will benefit more patients. conditions: Ameloblastoma studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study is a single-arm study that does not involve randomization or blinding, nor does it establish a parallel control group and uses external control. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Dabrafenib measure: objective response rate measure: Relapse-free survival sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06264765 id: 22-12-23 briefTitle: Scalp Block -Craniotomi acronym: scalp block overallStatus: RECRUITING date: 2024-01-01 date: 2025-01-01 date: 2026-01-01 date: 2024-02-20 date: 2024-02-20 name: Aydin Adnan Menderes University class: OTHER briefSummary: Postoperative pain after craniotomy is an important clinical problem as it can lead to hypertension and increased intracranial pressure. Multimodal analgesia methods are performed by anesthesiologists in different ways depending on the anesthetist's preference.
In addition, both techniques have been shown in studies to provide intraoperative hemodynamic stabilization in addition to their effects on postoperative pain. Although there are many studies on both techniques, the number of studies comparing scalp block with infiltration technique is very limited. Therefore, postoperative use of scalp block and incisional infiltration for postoperative pain after craniotomy is recommended. conditions: Hemodynamic Instability studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized double blinding primaryPurpose: OTHER masking: DOUBLE maskingDescription: Blind patients and postoperative follow-ups will not know which group the patient is in the study. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 62 type: ESTIMATED name: scalp block name: Incisional infiltration measure: opioid consumption measure: The Numeric Rating Scale (NRS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ferdi Gülaştı status: RECRUITING city: Aydın zip: 09020 country: Turkey name: Ferdi Gülaştı role: CONTACT email: ferdigulasti@gmail.com lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06264752 id: STUDY20120008 id: R01DK121730 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK121730 briefTitle: Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury acronym: MEnD-AKI overallStatus: ENROLLING_BY_INVITATION date: 2024-02-15 date: 2026-01 date: 2026-04 date: 2024-02-20 date: 2024-02-20 name: University of Pittsburgh class: OTHER name: University of Florida name: University of Pittsburgh Medical Center name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults. conditions: Acute Kidney Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a prospective, randomized, interventional controlled trial at eight hospitals within the UPMC health-system. Researchers will randomize 39 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. Hospital service clusters will be allocated 1:1 to the intervention or usual care with a web-based system to maintain concealment using a randomized block design. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Statisticians performing the analysis will be blinded to the treatment allocation.
The investigators will randomize clusters to intervention and control within strata defined hospitals to adjust for inherent subgroup differences. The allocation sequence list will be maintained by the data management team (DMT) using a secure web-based system where assignments will be maintained and accessed by the CDSS. Pharmacists will only receive alerts for patients of physicians randomized to the intervention. whoMasked: OUTCOMES_ASSESSOR count: 625 type: ESTIMATED name: Level A name: Level B name: Passive Alert measure: Major Adverse Kidney Events within 30 days of randomization (MAKE30) measure: Progression of AKI from time of Level B intervention (first alert generated) to hospital discharge measure: AKI Intensity: Duration of AKI for all stages; Duration of AKI Stage 2; Duration of AKI stage 3 measure: Nephrotoxic burden sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UPMC Altoona city: Altoona state: Pennsylvania zip: 16601 country: United States lat: 40.51868 lon: -78.39474 facility: UPMC Horizon city: Farrell state: Pennsylvania zip: 16121 country: United States lat: 41.21228 lon: -80.49674 facility: UPMC McKeesport city: McKeesport state: Pennsylvania zip: 15132 country: United States lat: 40.34785 lon: -79.86422 facility: UPMC Jameson city: New Castle state: Pennsylvania zip: 16105 country: United States lat: 41.00367 lon: -80.34701 facility: UPMC Magee city: Pittsburgh state: Pennsylvania zip: 15213 country: United States lat: 40.44062 lon: -79.99589 facility: UPMC Presbyterian/Montefiore city: Pittsburgh state: Pennsylvania zip: 15213 country: United States lat: 40.44062 lon: -79.99589 facility: UPMC Shadyside city: Pittsburgh state: Pennsylvania zip: 15232 country: United States lat: 40.44062 lon: -79.99589 facility: UPMC Williamsport city: Williamsport state: Pennsylvania zip: 17701 country: United States lat: 41.24119 lon: -77.00108 hasResults: False
nctId: NCT06264739 id: 22-12-23/2 briefTitle: Erector Spinae Block -Dexmedetomidine acronym: esp -dex overallStatus: RECRUITING date: 2024-01-01 date: 2025-01-01 date: 2026-01-01 date: 2024-02-20 date: 2024-02-20 name: Aydin Adnan Menderes University class: OTHER briefSummary: Postoperative pain is common after spinal surgeries, including lumbar disc surgery. Surgical anesthesia and perioperative analgesic regimen are aimed at complete intraoperative amnesia, deep analgesia, effective control of autonomic responses and rapid discharge from the hospital.
Although there are many studies on the use of these techniques for postoperative analgesia, the number of data comparing these techniques that can be used in meta-analyses is low. In our study, investigators aimed to compare the effects of remifentanil and dexmedetomidine accompanied by ESP block, which are different multimodal analgesia methods, on pain. conditions: Postoperative Acute Pain conditions: Opioid Consumption studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized double blinding primaryPurpose: OTHER masking: DOUBLE maskingDescription: Blindness patients and those who follow up after surgery will not know which group is in the study. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 74 type: ESTIMATED name: esp Dexmedetomidine (dekstomid) name: esp remifentanyl (ultiva) measure: opioid consumption measure: The Numeric Rating Scale (NRS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ferdi Gülaştı status: RECRUITING city: Aydın zip: 09020 country: Turkey name: Ferdi Gülaştı role: CONTACT email: ferdigulasti@gmail.com lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06264726 id: 23-0254 id: R01HL150909 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL150909 briefTitle: CommunityRx-Cardiovascular Disease acronym: CRx-CVD overallStatus: RECRUITING date: 2024-03-12 date: 2025-03-12 date: 2025-03-12 date: 2024-02-20 date: 2024-04-12 name: University of North Carolina, Chapel Hill class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The goal of this single arm pre-test post-test design study is to test the impact of providing patients with information about community-based resources to address health-related social needs and cardiometabolic health in rural African American patients. The main question it aims to answer is:
* 2 text messages with reminders about the HealtheRx and access to the community resource navigator conditions: Cardiovascular Diseases conditions: Self Efficacy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 325 type: ESTIMATED name: HealtheRx measure: Change in participant self-efficacy for finding community resources measure: Change in participant knowledge of community resources measure: Change in participant utilization of community resources sex: ALL minimumAge: 2 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: OIC Family Medical Center - Fairview status: RECRUITING city: Rocky Mount state: North Carolina zip: 27801 country: United States name: Jesslyn Pope role: CONTACT email: jpope@oicone.org lat: 35.93821 lon: -77.79053 facility: OIC Family Medical Center - Happy Hill status: RECRUITING city: Rocky Mount state: North Carolina zip: 27804 country: United States name: Jesslyn Pope role: CONTACT email: jpope@oicone.org lat: 35.93821 lon: -77.79053 hasResults: False
nctId: NCT06264713 id: CE/2023_041 briefTitle: Immersive Virtual REality for Treatment of Unilateral Spatial NEglect Via Eye-tracking Biofeedback acronym: IRENE overallStatus: RECRUITING date: 2023-11-01 date: 2025-11-01 date: 2025-12-01 date: 2024-02-20 date: 2024-02-22 name: I.R.C.C.S. Fondazione Santa Lucia class: OTHER briefSummary: The purpose of this study is to evaluate the effects of a treatment using virtual reality on the recovery of unilateral spatial neglect. The investigators hypothesize that the experimental group underwent to a protocol of active exercises within the virtual environment will show an improvement in the exploratory functions of the left hemispace, investigated with specific scales and clinical tests. conditions: Neglect, Hemispatial conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised Clinical Trial primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double blind randomisation. The patients and their families/caregivers are blinded with respect to the group allocation. The assessors are not informed about the group allocation for the entire period of the study. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Immersive Virtual Reality name: Sham Immersive Virtual Reality measure: Changes in the Behavioural Inattention Test measure: Changes in the Copying drawings with or without programming elements measure: Changes in the Barrage Test measure: Changes in the Wundt Justrow area illusion test measure: Changes in the Kessler Foundation Neglect Assessment Process measure: Changes in the Stroke Specific Quality of Life Scale measure: Changes in the Fugl-Meyer Assessment scale measure: Changes in reaction time e time of fixation sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Santa Lucia Foundation status: RECRUITING city: Rome state: Lazio zip: 00142 country: Italy name: Valeria Verna, MSc role: CONTACT phone: 0651501907 name: Valeria Verna, MSc role: PRINCIPAL_INVESTIGATOR name: Marco Tramontano, PhD role: SUB_INVESTIGATOR name: Alex Martino Cinnera, PhD role: SUB_INVESTIGATOR name: Viviana Betti, PhD role: SUB_INVESTIGATOR name: Matteo Marucci, PhD role: SUB_INVESTIGATOR name: Luisa Magnotti, BSc role: SUB_INVESTIGATOR name: Alessandro Matano, MSc role: SUB_INVESTIGATOR name: Aurora Tavernese, MSc role: SUB_INVESTIGATOR name: Paolucci Stefano, MD role: SUB_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06264700 id: STUDY00003303 id: R44HL169085 type: NIH link: https://reporter.nih.gov/quickSearch/R44HL169085 briefTitle: Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness acronym: ADHERE overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-12 date: 2025-12 date: 2024-02-20 date: 2024-02-20 name: Nationwide Children's Hospital class: OTHER name: Ann & Robert H Lurie Children's Hospital of Chicago name: Hasbro Children's Hospital name: National Institutes of Health (NIH) name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This study is for caregivers of young children with sickle cell disease and adolescents with sickle cell disease who are currently prescribed hydroxyurea and are receiving care at one of the study sites. The study will assess retention and engagement during a pilot randomized control trial comparing video directly observed therapy (VDOT) to attention control. We also hope to understand more about patient and family preferences longer-term adherence monitoring and intervention.
Participants will use an electronic adherence monitor (provided by the study team) to measure how often they are taking their hydroxyurea. Participants will also be asked to complete questionnaires throughout the study period to provide information about their expectations for, experience with, and satisfaction with the study materials. conditions: Sickle Cell Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: After completing a one to three-month run-in period, participants will be randomized to receive six months of either VDOT or attention control. All participants will then complete six months of ongoing monitoring during which VDOT patients will receive intermittent communication to encourage adherence and both groups will continue to use their electronic adherence monitors. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The investigators will be blinded to prevent the possibility of any differential treatment that could affect the ability of the study team to evaluate the impact of VDOT on hydroxyurea adherence. As such, a statistician will create a randomization model and study staff will facilitate communication with participants as well as between participants and the VDOT team. whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Video Directly Observed Therapy (VDOT) name: Health Reminder Tip Alerts measure: Retention Rate measure: Sustained Engagement measure: Electronic Adherence measure: Pediatric SCD Medication Self-Management Questionnaire measure: Frequency of acute care visits (ACS and VOC), ICU admissions, and LOS for hospitalizations measure: Laboratory Studies (i.e. MCV, HbF) measure: Treatment Satisfaction measure: Participant Satisfaction sex: ALL minimumAge: 11 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Lurie Children's Hospital city: Chicago state: Illinois zip: 60611 country: United States name: Sherif Badawy, MD role: CONTACT phone: 312-227-4836 email: sbadawy@luriechildrens.org lat: 41.85003 lon: -87.65005 facility: Hasbro Children's Hospital city: Providence state: Rhode Island zip: 02903 country: United States name: Patrick McGann, MD, PhD role: CONTACT phone: 617-519-9555 email: patrick_mcgann@brown.edu lat: 41.82399 lon: -71.41283 hasResults: False
nctId: NCT06264687 id: HepcidinIVIron briefTitle: Hepcidin After Intravenous Iron Treatment overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-05-31 date: 2024-05-31 date: 2024-02-20 date: 2024-02-20 name: Pierre-Alexandre Krayenbühl class: OTHER briefSummary: The aim of this study is to investigate the hepcidin hormone response after intravenous iron administration. conditions: Iron Deficiency (Without Anemia) studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 10 type: ESTIMATED measure: Serum Hepcidin Change sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False